Prr11-flox Mouse
Common Name
Prr11-flox
제품 ID
S-CKO-09923
Backgroud
C57BL/6JCya
품종 계통계통 ID
CKOCMP-270906-Prr11-B6J-VA
상태
이 마우스 계통을 논문에서 사용할 경우, “Prr11-flox Mouse (카탈로그 번호 S-CKO-09923)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
구매 가능한 제품 종류
연령
Genotype
성별
수량
표준 제공 조건은 최소 3마리의 이형접합(heterozygous) 보균자를 보장합니다. 동형접합(homozygous) 보균자 및/또는 특정 성별에 대한 브리딩 서비스도 제공됩니다.
기본 정보
품종 계통
Prr11-flox
품종 계통계통 ID
CKOCMP-270906-Prr11-B6J-VA
유전자명
제품 ID
S-CKO-09923
유전자 별칭
B930067F20Rik
배경
C57BL/6JCya
NCBI ID
변형 내용
Conditional knockout
염색체
Chr 11
Phenotype
Datasheet
적용 분야
--
품종 계통 설명
Ensembl 전사체 ID
ENSMUST00000051395
NCBI 전사체 ID
NM_175563
타겟 영역
Exon 3~4
유효 영역 크기
~2.6 kb
유전자 연구 개요
Prr11, short for Proline rich 11, is a proline-rich protein coding gene located on chromosome 17q22-23. Initially linked to cell-cycle progression, it is now known to play crucial roles in multiple cellular processes such as proliferation, colony formation, migration, invasion, apoptosis, autophagy, and chemotherapy resistance via various signaling pathways in several solid tumors [1].
In glioblastoma, depletion of Prr11 significantly sensitizes cells to temozolomide by inducing ferroptosis. Mechanistically, Prr11 binds to and stabilizes dihydroorotate dehydrogenase (DHODH), leading to ferroptosis-resistant glioma [2].
In clear cell renal cell carcinoma (ccRCC), Prr11 silencing reduces cell proliferation and migration in vitro and in vivo. Prr11 induces degradation of the E2F1 protein, affecting cell-cycle progression, and is a target gene of c-Myc [3].
In bladder urothelial carcinoma, high Prr11 expression is associated with poor outcomes and correlates with tumor mutational burden and immune cell infiltration [4].
In early pregnancy, Prr11 promotes trophoblast cell motility by binding to the ARP2/3 complex [5].
In pan-cancer, interfering with Prr11 inhibits cell proliferation and migration, and Prr11 influences cell-cycle progression by regulating PTTG1 expression through interaction with E2F1 [6].
In colorectal cancer, Prr11 silencing suppresses cell proliferation, invasion, migration, and tumor growth by inhibiting the EGFR/ERK/AKT pathway via restraining CTHRC1 expression [7].
In pancreatic cancer, high Prr11 protein expression is associated with adverse clinicopathological features and shorter overall survival [8].
In glioma, Prr11 is a promising diagnostic and prognostic predictor, and its knockdown suppresses cell viability, migration, and cell-cycle progression, and induces apoptosis and autophagy [9].
In non-small cell lung cancer cells, Prr11 recruits the ARP2/3 complex to promote filopodia formation, focal adhesion turnover, and cell motility [10].
In conclusion, Prr11 is a key gene involved in multiple cellular processes and is associated with various malignancies. Studies on Prr11, especially through loss-of-function experiments, have revealed its significance in tumorigenesis, chemotherapy resistance, and immune-related aspects in different cancer types, providing potential therapeutic targets for cancer treatment.
References:
1. Han, Wei, Chen, Liang. 2022. PRR11 in Malignancies: Biological Activities and Targeted Therapies. In Biomolecules, 12, . doi:10.3390/biom12121800. https://pubmed.ncbi.nlm.nih.gov/36551227/
2. Miao, Zong, Xu, Lei, Gu, Wei, Ji, Jing, Chen, Juxiang. 2024. A targetable PRR11-DHODH axis drives ferroptosis- and temozolomide-resistance in glioblastoma. In Redox biology, 73, 103220. doi:10.1016/j.redox.2024.103220. https://pubmed.ncbi.nlm.nih.gov/38838551/
3. Chen, Siming, He, Zhiwen, Peng, Tianchen, Xiao, Yu, Wang, Xinghuan. 2021. PRR11 promotes ccRCC tumorigenesis by regulating E2F1 stability. In JCI insight, 6, . doi:10.1172/jci.insight.145172. https://pubmed.ncbi.nlm.nih.gov/34499617/
4. Ni, Wenpeng, Yi, Lijuan, Dong, Xiaoru, Wei, Qingling, Yuan, Chunlei. 2023. PRR11 is a prognostic biomarker and correlates with immune infiltrates in bladder urothelial carcinoma. In Scientific reports, 13, 2051. doi:10.1038/s41598-023-29316-2. https://pubmed.ncbi.nlm.nih.gov/36739300/
5. Zhu, Pengfei, Dou, Chengli, Song, Zhijiao, Wu, Xueqing, Miao, Yiliang. . ELF1/PRR11/ARP2/3 promoted trophoblast cells proliferation and motility in early pregnancy. In American journal of reproductive immunology (New York, N.Y. : 1989), 90, e13758. doi:10.1111/aji.13758. https://pubmed.ncbi.nlm.nih.gov/37641376/
6. Zhang, Haibo, He, Ziqing, Qiu, Li, Lin, Shudai, Du, Hongli. 2022. PRR11 promotes cell proliferation by regulating PTTG1 through interacting with E2F1 transcription factor in pan-cancer. In Frontiers in molecular biosciences, 9, 877320. doi:10.3389/fmolb.2022.877320. https://pubmed.ncbi.nlm.nih.gov/36060253/
7. Ma, Hualing, Yang, Weigui, Wang, Xiufang, Dai, Gang. . PRR11 Promotes Proliferation and Migration of Colorectal Cancer through Activating the EGFR/ERK/AKT Pathway via Increasing CTHRC1. In Annals of clinical and laboratory science, 52, 86-94. doi:. https://pubmed.ncbi.nlm.nih.gov/35181621/
8. Olsson Hau, Sofie, Wahlin, Sara, Cervin, Sophie, Karnevi, Emelie, Jirström, Karin. 2021. PRR11 unveiled as a top candidate biomarker within the RBM3-regulated transcriptome in pancreatic cancer. In The journal of pathology. Clinical research, 8, 65-77. doi:10.1002/cjp2.238. https://pubmed.ncbi.nlm.nih.gov/34379360/
9. Han, Wei, Chen, Liang. 2023. Predictive significance of PRR11 in prognosis and immune infiltration of glioma patients. In Molecular carcinogenesis, 62, 975-990. doi:10.1002/mc.23539. https://pubmed.ncbi.nlm.nih.gov/37036189/
10. Wei, Zhili, Wang, Ru, Yin, Xun, Jin, Guoxiang, Zhang, Chundong. 2021. PRR11 induces filopodia formation and promotes cell motility via recruiting ARP2/3 complex in non-small cell lung cancer cells. In Genes & diseases, 9, 230-244. doi:10.1016/j.gendis.2021.02.012. https://pubmed.ncbi.nlm.nih.gov/35005120/
품질 관리 기준
정자 검사
동결 보존 전: 정자 농도 측정 및 정자 생존율 평가.
동결 보존 후: 각 배치에서 동결 보존된 정자 바이알 1개를 선택하여 체외수정(in vitro fertilization)에 사용합니다.
Environmental Standards:
SPFAvailable Region:
GlobalSource:
Cyagen문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.
